Form 4 for BCAX Bicara Therapeutics Inc.
Accepted 2025-12-29 00:00:00 ET · period of report 2025-12-26 · accession 0001628280-25-059045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-29 | 2025-12-26 | BCAX | Cohlhepp Ryan | Pres, COO, Dir | M - OptEx | $4.44 | +25.0K | 214.1K | +13% | +$111.0K |
| D | 2025-12-29 | 2025-12-26 | BCAX | Cohlhepp Ryan | Pres, COO, Dir | M - OptEx | $0.00 | -25.0K | 39.9K | -39% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-26 | M | A | 25,000 | $4.44 | 214,141 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-12-26 | M | D | 25,000 | $0.00 | 39,909 | D | $4.44 · — to 2032-10-04 | 25,000 Common Stock | (F2) The shares underlying this option vest in sixteen equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date. |